29 October 2024
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS LIMITED
Notification of Preliminary Results and Annual General Meeting
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for shareholders of the Company that the Board of Directors decided at their meeting held on 28 October 2024. Please see further detail as follows:
| 1. | To recommend the approval of the Financial Statements for the year ended 30 June, 2024 | The Audited Financial Statements for the year ended 30 June 2024 have been approved. The full accounts are expected to be announced by 7 November 2024 |
| 2. | Date & Time of 48th Annual General Meeting ("AGM") of the Company for the year ended 30 June, 2024 | 29 December 2024 at 10.30 A.M. Bangladesh Time |
| 3. | Venue of AGM | Virtual Platform (Zoom Meeting)
|
| 4. | Proposed Dividend for the year ended 30 June, 2024 | 40% Cash Dividend (i.e. Tk 4.00 per Share) |
| 5. | Record date | 25 November 2024 |
| 6. | Proposed change of Company name | Resolved to pass a Special Resolution to change the name of the Company from "Beximco Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC" in compliance to the Companies Act, 1994 (amended in 2020), subject to the approval of the Shareholders in the 48th AGM of the Company to be held on 29th December, 2024 as a matter of special business |
Comparative Financial Disclosures:
Beximco Pharmaceuticals Limited and its Subsidiaries (Consolidated)
| Particulars | Year ended 30 June 2024 | Year ended 30 June 2023 |
| Net Profit after Tax | Tk. 5,866,771,470 | Tk. 4,524,468,490 |
| Earnings Per Share (EPS) | Tk. 13.07 | Tk. 10.34 |
| Net Asset Value (NAV) | Tk. 47,949,964,744 | Tk. 43,680,703,738 |
| Net Asset Value per share (NAVPS) | Tk. 107.48 | Tk. 97.91 |
| Net Operating Cash Flow Per Share (NOCFPS) | Tk. 18.75 | Tk. 13.64 |
Beximco Pharmaceuticals Limited (Stand-alone)
| Particulars | Year ended 30 June 2024 | Year ended 30 June 2023 |
| Net Profit after Tax | Tk. 5,610,513,429 | Tk. 4,588,008,908 |
| Earnings Per Share (EPS) | Tk. 12.58 | Tk. 10.28 |
| Net Asset Value (NAV) | Tk. 47,391,484,377 | Tk. 43,341,239,142 |
| Net Asset Value per share (NAVPS) | Tk. 106.23 | Tk. 97.15 |
| Net Operating Cash Flow Per Share (NOCFPS) | Tk. 17.46 | Tk. 12.96 |
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott / Adam Dawes
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Sam Purewal
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5700 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.